A sensitive and accurate high-performance liquid-chromatography method was developed and validated for the simultaneous determination of pyrazinamide (PZA), isoniazid (INH), rifampicin (RFP) and acetylisoniazid (AcINH) in human plasma. Separation was performed on a Max-RP C12 column using gradient elution and a flow-rate program. The mobile phase was methanol-acetonitrile-buffer (20 mM of heptanesulfonic acid sodium, pH 2.5) with a ratio of 10:8:82 (v/v/v) at the initial phase. All calibration curves had good linearity (r 2 > 0.99) between the test ranges. The intra-and inter-day precision was less than 8.8% in good accuracy (<15%). The limit of detection with a signal-to-noise (S/N) of 3 was 0.014, 0.009, 0.023 and 0.054 µg mL -1 for PZA, AcINH, INH and RFP, respectively. The method was selective, sensitive and reliable, and is a good alternative for routine therapeutic drug monitoring of the four compounds during the treatment of tuberculosis patients.
Introduction
Tuberculosis (TB) is a worldwide pandemic infectious disease, which causes the deaths of millions of people each year. The vast majority of TB deaths are in the developing world, with more than half occurring in Asia. 1 The co-administration of isoniazid (INH), rifampicin (RFP) and pyrazinamide (PZA) is the most important regimen used in the initial-phase treatment of TB patients, 2 and most patients respond well. However, some patients experience treatment failure because of a low blood drug concentration. 3, 4 Acetylisoniazid (AcINH), the major metabolite of INH, is metabolized by N-acetyltransferase type 2 in the liver, including slow and fast acetylator phenotypes. 5 The side effects and therapeutic effectiveness of INH are different from that of the acetylator phenotype. It is then helpful and convenient to conduct combined measurements of AcINH for determining the acetylator phenotype to adjust the dose and to reduce the side effects of INH. 6 After adjusting the dose treatment according to blood drug concentration monitoring, most patients of treatment failure were successfully treated. 3, 7 Therefore, plasma drug concentration monitoring is very important to improve the effectiveness of the therapy of TB patients.
Several HPLC methods [8] [9] [10] [11] [12] [13] have been developed to analyze PZA, INH and RFP in pharmaceutical formulations within a reasonable running time. However, these methods could not be applied to the determination of drugs in plasma or urine because of the complexity of these samples. Some HPLC methods [14] [15] [16] were developed to analyze the drugs in biological samples. However, these methods analyzed only one or two drugs in plasma, 12, [14] [15] [16] in urine 10 or in cells, 17 or have the limitation of complicated derivatization of the samples. 14 Unsalan 18 had reported an LC method for the simultaneous determinations of PZA, INH and RFP within 11 min using a 150 mm long C18 column. Unfortunately, it could not be repeated, and it was involved in the sample preparation of INH and PZA, RFP separately. It then had to be injected two times for each sample to analyze PZA, INH and RFP. LC-MS is selective and sensitive, and several HPLC-MS methods 17, [19] [20] [21] [22] [23] have been reported. However, it is very expensive and not always available, particularly in remote areas of developing countries. Therefore, HPLC is still the most common and economical method for the simultaneous determinations of anti-tuberculosis drugs.
In this study, we developed and validated an HPLC coupled with a diode array detection (HPLC-DAD) method for the simultaneous determinations of PZA, INH, RFP and AcINH in TB patient's plasma, using a gradient elution mode on a C12 column. The method described here has several advantages: it is almost as sensitive as LC-MS 22 due to the narrow and sharp peaks; the sample pretreatment is simple and simultaneous determinations of the four drugs have been obtained. On the other hand, it is the first time to use a C12 column for the simultaneous determinations of PZA, INH, RFP and AcINH. The C12 column showed good performances of separation, selectivity, and peak shape for the determination of the drugs. This method was proved to be sensitive, reliable and accurate, and was successfully applied to the therapeutic drug monitoring of TB patients after the oral administration of PZA, INH and RFP.
Experimental

Reagents and chemicals
INH, RFP and PZA were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). All compounds were above 99% purity. AcINH was synthesized in house using a method previously described by Fox and Gibas. 24 Terramycin was used as an internal standard (IS), and was purchased from Sigma (St. Louis, MO). Methanol, acetonitrile and 1-heptanesulfonic acid sodium were of HPLC grade and purchased from Fisher Scientific (Fair Lawn, NJ). All other reagents were of analytical grade and purchased from Guangzhou Chemical Reagent Factory (Guangzhou, China). Deionized water was obtained from a Milli-Q analytical deionization system (Millipore, Bedford, MA).
Chromatography
HPLC analysis was carried out on a Shimadzu LC-20A system (Kyoto, Japan) equipped with a controller, a quaternary gradient pump, an ultraviolet DAD detector, an autosampler, a column oven and an on-line degasser. The HPLC column was a Synergi Max-RP C12 (250 mm × 4.6 mm, 4 µm particle size) (Phenomenex, USA), protected by a RRLC on-line filter (Agilent Technologies, USA). The column temperature was held at room temperature. The mobile phase comprised methanol (solution A), acetonitrile (solution B) and buffer of 20 mM 1-heptanesulfonic acid sodium (pH 2.5 adjusted with H3PO4) (solution C) using a gradient elution program. The composition of the initial mobile phase was 10:8:82 (v/v/v) of solutions A, B, C with a flow rate of 0.8 mL min -1 . After 6 min, the mobile phase was changed linearly to 0:65:35 (v/v/v) and a flow rate of 1.5 mL min -1 occurred at 14 min, and was then kept until 19 min. At 19.5 min, the mobile phase was changed to the initial composition and the flow rate to 1.2 mL min -1 ; these conditions were kept until 24.5 min. Then, the flow rate was put back to 0.8 mL min -1 at 25 min, and kept for 1 min before the next injection. The injection volume was 20 µL. The compounds were detected in the range of 220 -390 nm. The monitoring and quantification wavelengths were 268, 265, 264 and 341 nm for PZA, AcINH, INH and RFP, respectively.
Preparation of standards and quality control samples
Stock solutions of PZA, INH, AcINH, RFP and IS at a concentration of 1.00 mg mL -1 were prepared in methanol, respectively. Different volumes of the stock solutions of PZA, INH, AcINH and RFP were combined and diluted with methanol to produce a working standard at the desired concentrations. An internal standard working solution was prepared by diluting the stock solution with methanol to 100 µg mL -1 . All of the solutions were stored in brown glass bottles at -40 C.
Calibration The calibration standards and QCs were extracted on each day of the analysis with the procedure used for plasma, described below.
Sample preparation
To a 200-µL aliquot of each standard, blank and QC samples, a 10 µL of the internal working solution and a 1 mL of acetonitrile were added. After mixing vigorously on a vortex shaker for 2 min, the samples were centrifuged at 13000 rpm for 10 min. The clear supernatants were transferred and dried down under a nitrogen stream at room temperature. The residue was reconstituted in 200 µL of methanol.
After being centrifuged at 13000 rpm for 5 min, a 20-µL aliquot of the solution was injected into the HPLC system.
Method validation
Linearity. Calibration plots were prepared by assaying plasma standards containing 8 concentrations of PZA (0.1 -40 µg mL ). Calibration curves were constructed by the plotting peak area ratio (y-axis) of the target compounds to the IS versus the nominal concentrations (x-axis) with a weighting (1/x 2 ) least-squares linear regression. Precision and accuracy. The system precision was evaluated by six consecutive injections of post-spiked sample at 5 µg mL -1 of the target compounds and IS. The precision was expressed as the relative standard deviation (RSD, %) of the retention time and the area of the target compounds and IS.
To evaluate the intra-day precision and accuracy, QC samples (n = 6) at low, middle and high concentrations were extracted in one batch. For the assay of the inter-day precision and the accuracy, five consecutive batches of QC samples were made by the same procedure on five different days. Each day, a freshly prepared calibration curve was constructed when the QC samples were extracted. The precision was reported as the relative standard deviation (RSD, %) and the accuracy as the relative error (RE, %). Recovery, LOD and LLOQ. The recoveries were assessed by comparing the peak area of the target compounds extracted from QC samples to those of the same concentration of target compounds spiked into blank-plasma post-extracts. Five repeats were carried out on low, middle and high levels of the QC samples. The recovery of IS was evaluated at a concentration of 5.0 µg mL -1 , followed the same procedure as that for the target compounds.
The limit of detection (LOD) was defined as the concentration with a signal-to-noise (S/N) of at least 3. The lower limit of quantification (LLOQ) was defined as the lowest concentration on the calibration plot with a precision of <20% and an accuracy (RE, %) within ± 20%. 25 
Stability.
Stability experiments were carried to assess the stability of the target compounds in stock solutions, post-extracted solutions and plasma samples.
The short-term stability of the target compounds in the plasma was evaluated by leaving QC samples at room temperature for 6 h. A freeze-thaw stability test was performed by determining QC samples after 3 freeze (-40 C) and thaw (room temperature) cycles. The long-term stability was determined by storing QC samples at -40 C for 4 weeks. The post-extracted stability was measured by testing the extract solution of QC samples kept at room temperature for 24 h. All QC samples for stability testing included low, middle and high concentrations, and each concentration had five repeats. During each analytical run, a standard curve was constructed to calculate the concentration of the target compounds.
The working solution stability was assessed at room temperature for 24 h. The stock solution stability was also evaluated by keeping the stock solution at -40 C for two months.
Results and Discussion
Opitmization of chromatography
Due to the distinctively different polarities, largely different chromatographic behaviors of the target compounds were observed. To shorten the separate time and to improve the peak symmetry, several chromatographic parameters, including the column, the component and the pH of the buffer, the ratio of methanol and acetonitrile, the flow rate of the mobile phase and the elution model were optimized.
Appropriate retention times, but severely tailing peaks, were obtained for PZA, INH and AcINH when separation was performed on a C18 or C8 column under the optimal conditions. However, a too-long retention time (more than 28 min) for RFP was obtained even when using a sharp gradient program which caused a severe drift of the baseline. A reasonable retention time was obtained under the optimal conditions when a CN-column was used, but this led to a very broad peak, which resulted in high LODs and LLOQs.
After many tests, a Synergi Max-RP C12 column (4.6 × 250 mm, 4 µm particle size) was selected, since symmetric and sharp peaks were obtained with an acceptable retention time (less than 19 min) under the optimal chromatographic conditions (Table 1) . Heptanesulfonic acid sodium of 20 mM was selected as the ion-pair reagent in the mobile phase after comparing the separation under different concentrations of heptanesulfonic acid sodium. A low pH can help to delay the elution of AcINH and INH, but has less effects on PZA and RFP. Finally, 20 mM of heptanesulfonic acid sodium and pH 2.5 were selected for the buffer solution.
Increasing the acetonitrile content can sharpen peak shape, and speed up the elution of RFP. However, too much of acetonitrile can result in an asymmetric peak and a too-fast elution of PZA, AcINH and INH. At last, 10% methanol, 8% acetonitrile and 82% buffer were chosen for the initial mobile phase. To quicken the elution of RFP, a gradient-elution program and a flow-rate program were used. After a number of tests, the chromatographic conditions described in detail in the Chromatography section was determined to be the best option in terms of the peak shape, running time and reproducibility.
Since a C18 column was the most-common in used in routine work, the proposed method (C12 column) was further compared with the C18 column method concerning the retention time, peak tailing factors and peak width (Table 1) . In Table 1 , the retention time of AcINH, obtained by a C12 column is longer than that obtained by the C18 column. However, the retention times of other compounds and the last eluting compound (RFP) of the C12 column were shorter than that of the C18 column, which resulted in a shorter running time for each sample. Furthermore, the peaks obtained by the C12 column were more symmetric and sharper than those obtained by the C18 column (Table 1) . A statistical comparison of the retention time of RFP (the last eluting compound), tailing factors and peak width were further carried out by statistical software (SPSS 13.0); the statistical results demonstrated that the C12 column was significantly different from that of the C18 column (P < 0.05).
The max absorbance wavelengths of 268, 265 and 264 nm were selected for monitoring and quantification of PZA, AcINH and INH, respectively. A wavelength of 341 nm was selected for the quantification of RFP, because RFP was sensitive enough, and had no interferences at this wavelength. In this study, terramycin was selected as the IS for all of the target compounds because of it's similarity of recovery, UV absorbance at the quantitative wavelength of each target compound and appropriate retention time. Figures 1 and 2 show typical chromatograms at 268 and 341 nm of blank plasma, blank plasma spiked with 2 µg mL -1 target analytes and 5 µg mL -1 of IS, and a patient plasma sample at 2 h after an oral administration of 1.5 g of PZA, 0.3 g of INH and 0.45 g of RFP. Under the optimum chromatographic conditions, all of the target compounds and IS were well separated within 19 min, as well as in sharp and symmetric peak shapes ( Figs. 1 and 2) . The retention times of PZA, AcINH, INH, RFP and IS were 5.23, 9.27, 10.35, 18.11 and 14.83 min, respectively. There was no significant interference at the retention time of the target compounds and IS. The peak purity was also evaluated by the purity index of the target compounds. The purity index (>0.98) showed that the peaks were pure enough, and no interference co-eluted with the target compounds and IS.
Sample extraction
Due to the strong polarity of PZA, AcINH and INH, it was not suitable for a liquid-liquid extraction or a solid-phase extraction method to extract the compounds from biological samples. Thus, a protein precipitation method was selected. Trifluoroacetic acid, trichloroacetic acid and perchloric acid are usually used for the protein precipitation of plasma samples. However, the recoveries of RFP were very low (10 -40%) with a large relative standard deviation (43 -64.5%) when trifluoroacetic acid, trichloroacetic acid and perchloric acid were used for protein precipitation.
To achieve a high extraction efficiency, conventional organic solvents (methanol, acetonitrile and acetone) were investigated. It was found that acetonitrile resulted in the most efficient extraction (recoveries above 83%, Table 2 ) than those by methanol (recoveries between 61 and 75%) and acetone (recoveries between 53 and 72%). At the same time, the chromatogram of real samples by acetonitrile protein precipitation had the least interference.
Finally, acetonitrile was selected for protein precipitation.
No endogenous interferences were observed at the retention time of the target compounds and IS. The LOD with a signal-to-noise (S/N) of 3 was 0.014, 0.009, 0.023 and 0.054 µg mL -1 for PZA, AcINH, INH and RFP, respectively. In our study, the on-column sensitivities (the quantity of drug injected on to the column per injection) of PZA, AcINH, INH and RFP were 0.28, 0.18, 0.46 and 1.08 ng, which were lower than those reported in the literature, 10, 18 and almost as sensitive as the LC-MS method (5.0, 0.1 and 1.0 ng of PZA, INH and RFP). 22 The LLOQs of PZA, AcINH, INH and RFP were 0.1, 0.05, 0.1 and 0.2 µg mL -1 , respectively. The LLOQs in our method were also lower than those reported in the literature. 10, 15, 18 Precision, accuracy and recovery. The system precision was evaluated by the precision of the retention time and the peak area of the target compounds, and IS after consecutive injections of post-spiked sample at 5 µg mL -1 of target compounds and IS (n = 6). The precision (RSD, %) of the retention time and the peak area were less than 1 and 5% (data not shown). The results indicated that the system precision was good enough, although the eluting gradient program and the flow rate program were used. The precision (RSD, %) of intra-and inter-day was less than 8.3 and 8.8%, respectively ( Table 3 ). The accuracy (RE, %) of intra-and inter-day ranged from -7.6 to 7.8%, and from -8.5 to -1.5% (Table 3) at LLOQ, low, middle and high QC levels for all compounds, respectively.
Method validation
The recoveries were also evaluated by comparing the peak area of the target compounds of QC samples to those of spiked in post-extracts at the same concentrations. The mean recoveries ranged from 83.7 to 91.0% with RSD% less than 8.1%, depending on the different compounds and the concentrations ( Table 2 ). The mean recovery of IS was 87.2% with an RSD of 4.9% (n = 15). Stability. The results of all stability tests (data not shown) indicated that the target compounds in human plasma were stable during sample storage, extraction and chromatographic analysis. The working standard solution was stable for at least 24 h at room temperature. The stock solution of the compounds was stable for at least two months when stored in brown bottles under -40 C (data not shown). The method can be used for the routine analysis of PZA, AcINH, INH and RFP in human plasma.
Application in therapeutic drug monitoring
The method was successfully applied to the therapeutic monitoring of PZA, AcINH, INH and RFP of 25 TB patients treated with an oral administration of 1.5 g of PZA, 0.3 g of INH and 0.45 g of RFP. Plasma samples were collected at 2 h after administration of anti-tuberculosis drugs. The plasma was analyzed within 3 h, or frozen immediately at -40 C until analysis. The plasma drug concentrations were obviously different, depending on different patients: PZA 7.95 -41.3 µg mL -1 (mean ± SD, 21.48 ± 8.59 µg mL -1 ), AcINH 0.4 -3.2 µg mL -1 (mean ± SD, 1.757 ± 0.57 µg mL -1 ), INH 0.4 -5.7 µg mL -1 (mean ± SD, 1.871 ± 0.86 µg mL -1 ) and RFP 1.82 -16.8 µg mL -1 (mean ± SD, 4.01 ± 2.32 µg mL -1 ). More applications of the method to plasma drug concentration monitoring are ongoing.
Conclusion
The proposed method is simple, precise and accurate. Because sharp and narrow peaks were obtained on the C12 column, compared to published HPLC methods, this method was more sensitive, even as sensitive as the LC-MS method. 22 The high sensitivity of the method made it useful when it was applied to a small amount of the sample.
The running time of the developed method may be a little long due to using a long analytical column (250 mm), compared to Unsalan's method, 18 in which a 150 mm C18 column was used, and only PZA, INH and RFP were analyzed. However, it was believed that, according to chromatographic theory, a shorter running time could be obtained if a 150 mm column becomes available.
All of these results indicate that the proposed method is a good alternative for the routine therapeutic drug monitoring of PZA, AcINH, INH and RFP in TB patient treatment. 
